期刊
CONTEMPORARY CHALLENGES IN AUTOIMMUNITY
卷 1173, 期 -, 页码 858-864出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1749-6632.2009.04615.x
关键词
CpG ODN; rituximab; TLR9; lymphoma; cytotoxicity
资金
- ROCHE
- Comites 22, 29, 35 et 72 de la Ligue Nationale contre le Cancer
- Celine et Stephane
- Franck et Stephane
- ARHOPH
- INCa (Institut National du Cancer
- MAb IMPACT network)
The anti-CD20 monoclonal antibody rituximab (RTX) has been applied to the therapy of B-cell proliferative disease, but a number of factors, such as the expression level of its target antigen, modulate its efficacy. Since unmethylated CpG-containing DNA sequences activate members of the immune systems, including B lymphocytes, their benefit to RTX treatment was determined on human lymphoma B-cell line cells. These Daudi cells expressed high endosomal level of the CpG Toll-like receptor 9, but CpG had effects neither on the viability, nor on the proliferation of the cells. In contrast, there appeared to be an increase in the expression of CD20, resulting in a higher efficiency of RTX for the killing of malignant Daudi cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据